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The emergence and spread of antibiotic resistance in bacterial
pathogens is dramatically undermining our ability to treat infection,
precipitating a public health crisis.1 The situation is particularly grave
in the case of infections caused by the ESKAPE pathogens (Enter-
ococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acineto-
bacter baumannii, Pseudomonas aeruginosa, and Enterobacter
species),2,3 a group of organisms whose name reﬂects their ability to
‘escape’ the action of existing antibacterial drugs. While the problem
presented by these pathogens could be effectively addressed
by developing novel antibacterial agents active against them, this is
proving easier said than done; the ﬁeld of antibacterial drug discovery
is now 30 years into a ‘Discovery Void’, a period during which no new
classes addressing the ESKAPE pathogens have successfully progressed
from discovery to clinic.4
One approach to identifying new antibacterial drug candidates
involves revisiting known natural product antibiotics that have not
been exploited for treating bacterial disease. A wealth of such
compounds exist, since of the c. 3000 antibiotics discovered to date,
only a handful of classes have been developed for clinical use.5 Of
particular interest amongst these unexploited antibiotics are those that
have already been documented to possess properties desirable in a
potential antibacterial drug to tackle infections caused by the ESKAPE
pathogens, for example, broad-spectrum activity and demonstrated
antibacterial efﬁcacy in animal models. While a proportion of such
compounds will likely have been considered and rejected for devel-
opment because they possess liabilities that went unreported in the
scientiﬁc literature, it is also conceivable that many have not been
rigorously evaluated as drug candidates. Furthermore, there are several
examples of antibiotics that were initially dismissed as drug candidates,
but were later revisited and successfully developed for clinical use (for
example, daptomycin, ﬁdaxomicin, pleuromutilins).4 Thus, we con-
sider a large-scale re-evaluation of known natural product antibiotics
to identify antibacterial drug candidates to be a worthwhile endeavor.
However, to redress the opacity of past antibacterial drug discovery
efforts4 and to prevent future duplication of effort, we consider it vital
that the scientiﬁc record comprehensively captures the details both for
compounds that such an analysis reveals to have potential
as antibacterial drug candidates, as well as those it does not.
Antibiotic MSD-819 (6-chloro-2-quinoxalinecarboxylic acid
1,4-dioxide; Figure 1a) was isolated from a strain of Streptomyces
ambofaciens by Merck Sharp & Dohme in the late 1960’s.6,7 This
compound was shown to exhibit broad-spectrum antibacterial activity
in a semiquantitative assay, producing measurable zones of inhibition
on agar around ﬁlter-paper discs impregnated with MSD-819
(1 mg ml− 1) against organisms that included Enterococcus faecalis,
Escherichia coli and some strains of S. aureus.7 In vivo activity of
MSD-819 was also demonstrated, with intraperitoneal administration
of the compound protecting mice infected with a lethal dose
of Proteus vulgaris, S. aureus or Salmonella schottmuelleri, at an ED50
of 0.11–1.25 mg per dose.7 Furthermore, a carboxamide derivative of
MSD-819 was reported to protect mice against lethal infection with
P. vulgaris when the compound was administered via the oral route.8
To further explore the biological properties of MSD-819, we sought
in the ﬁrst instance to purify the compound from the original
producer organism (S. ambofaciens var. MA-2870).7 Difﬁculties
encountered in generating sufﬁcient material for evaluation led us
instead to obtain the compound by chemical synthesis (Liverpool
ChiroChem, Liverpool, UK). The chemical structure and purity
(⩾99%) of MSD-819 were established by 1H NMR and LC-MS,
respectively (Supplementary Figure S1; analysis carried out by Liver-
pool ChiroChem). The antibacterial activity of MSD-819 was
evaluated against E. coli and representative ESKAPE strains. Minimum
inhibitory concentration (MIC) determinations, carried out according
to the CLSI guidelines for broth susceptibility testing,9 revealed
MSD-819 to display only weak antibacterial activity against both
Gram-positive and Gram-negative bacteria, with MICs of 128 mg l− 1
against E. faecium and E. coli (Figure 1b). In accordance with previous
ﬁndings, MSD-819 was inactive against P. aeruginosa and some strains
of S. aureus.7 While restricted intracellular accumulation often explains
the poor activity of many antibiotic classes against Gram-negative
bacteria,10 this phenomenon did not appear to adversely impact the
anti-Gram-negative activity of MSD-819; no signiﬁcant decrease in
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MIC was observed in E. coli BW2511311 deleted for the AcrAB-TolC
transporter, or upon permeabilization with polymyxin B
nonapeptide10 (data not shown).
The antibacterial properties of MDS-819 were further evaluated
against E. coli BW25113. In time-kill experiments,9 MSD-819 was
bactericidal at 4×MIC against rapidly growing cells, reducing an
exponential phase population of ~ 5× 105 CFU ml− 1 to below the
limit of detection (1 CFUml− 1) in 24 h (Figure 2a). In common with
most antibacterial drugs that exert a cidal action upon rapidly growing
bacteria, the compound had negligible effect on the viability of non-
growing cultures (bacteria from a stationary phase [16 h] culture,
re-suspended in spent medium to a cell density of ~ 5× 105
CFUml− 1) (Figure 2a). To evaluate the potential for MSD-819 to
select resistance, concentrated cultures of E. coli were spread onto agar
containing the antibiotic at 4×MIC.12 While the comparator agent
rifampicin selected mutants with reduced susceptibility at a frequency
of ~ 2× 10− 8, no mutants resistant to MSD-819 could be recovered
(limit of detection: 1.5 × 10− 10). Consequently, we consider MSD-819
to have low mutational resistance potential.13
The majority of antibiotics in clinical use exert their antibacterial
effects by interfering with the biosynthesis of cellular
macromolecules.13 We therefore initiated our investigation into the
antibacterial mode of action of MSD-819 by evaluating the effect of
the compound on the incorporation of radiolabelled precursors into
DNA, RNA and protein in E. coli.14 At 4×MIC, MSD-819 achieved
495% inhibition of all three macromolecular biosynthesis pathways
within 10 min, while the comparator agents ciproﬂoxacin, rifampicin
and tetracycline exhibited the expected preferential inhibition of DNA,
RNA and protein synthesis, respectively (Figure 2b). Non-speciﬁc
inhibition of macromolecular biosynthesis is a characteristic of
compounds that exert their antibacterial effects through perturbation
of the cytoplasmic membrane.15–17 We therefore evaluated the effect
of MSD-819 on bacterial membrane integrity, alongside comparator
agents, using the Live/Dead BacLight kit (Invitrogen, Paisley, UK).18
Incubation of E. coli with MSD-819 at 4×MIC caused essentially
complete loss of membrane integrity (99.5± 0.3%) in 10 min, a
similar result to that recorded for the known membrane-active agent,
colistin (94.1± 5.1%). By contrast, the non-membrane active anti-
biotic tetracycline caused no signiﬁcant reduction in membrane
integrity (7.5± 9.2%).
Compounds that act to perturb bacterial membranes often exert
similar effects on mammalian membranes, an undesirable property for
an antibacterial drug candidate. To evaluate the speciﬁcity of MSD-819
for bacterial membranes, we challenged equine erythrocytes with
4×MIC of MSD-819 for 60 min and monitored membrane integrity
by measuring leakage of hemoglobin at an absorbance of 540 nm.16
MSD-819 caused a substantially greater loss of mammalian membrane
integrity (39.9± 2.5%) than observed for the comparator agents,
colistin and tetracycline (16.6± 4.5% and 4.0± 4.0%, respectively).
We subsequently examined whether the ability of MSD-819 to
perturb mammalian membranes was associated with cytotoxic effects
on mammalian cells. Cytotoxicity was evaluated in human kidney-2
cells by measuring ATP levels (using the Adenosine 50-triphosphate
bioluminescent somatic cell assay kit, Sigma-Aldrich) after
6 h challenge with MDS-819. MSD-819 displayed an EC50 of
o256 mg l− 1, indicative of cytotoxic effects at concentrations close
to the bacterial MIC, implying that MSD-819 lacks prokaryotic
selectivity.
Bacterial strain MIC (mg/L)
Enterococcus faecium MRL 765793 128
Staphylococcus aureus SH1000 >256
Staphylococcus aureus ACC A790662 >256
Klebsiella pneumoniae 581346 256
Acinetobacter baumannii 581217 256
Pseudomonas aeruginosa PA01 >256
Pseudomonas aeruginosa PA14 >256
Enterobacter cloacae 583750 256
Escherichia coli IHMA 659048 128
Escherichia coli BW25113 128
Figure 1 Chemical structure (a) and antibacterial activity (b) of MSD-819.
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Figure 2 Effects of MSD-819 and comparator agents at 4×MIC on viability
and macromolecular biosynthesis pathways of E. coli BW25113. (a) Viability
of exponential and stationary phase cultures of E. coli exposed to
compounds for 24 h (level of detection, 1 CFU ml−1). NDC – no drug
control. (b) Effect of a 10 min exposure of E. coli to antibacterial agents on
incorporation of radiolabeled precursors into macromolecules. The datum
points represent the means of at least three independent experiments.
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Most antibacterial drugs approved for systemic use have an MIC
below, or close to, 1 mg l− 1.13 While the antibacterial activity of
MSD-819 against the ESKAPE pathogens is weak in comparison,
this should not alone rule this class of compound from further
consideration as a candidate for antibacterial chemotherapy, particu-
larly since chemical derivatization has been shown to boost its
antibacterial potency by 420-fold.8 However, the ﬁnding that the
membrane-perturbing mechanism by which MSD-819 exerts its
antibacterial effect also negatively impacts mammalian membranes,
and that the compound therefore lacks selectivity of action against
bacteria, indicates that MSD-819 does not represent a promising
candidate for medicinal chemistry to improve its antibacterial potency.
Future studies will seek to evaluate other previously unexploited
antibiotic classes to assess their potential as antibacterial drug
candidates.
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